
From the initial U.S. emergence of the coronavirus in early 2020, contract research organizations, or CROs, have been at the forefront of collaborating with pharmaceutical, biotech and medical device companies to develop innovative new medicines, treatments and equipment that improve patient outcomes.
Partnerships are more important than ever to help CROs as they navigate ongoing industry disruptions and uncertainty, supporting an enduring focus on key industry imperatives to accelerate scientific innovation, build operational agility, drive digital transformation and deliver a positive employee and patient experience.
Join leading experts to dive into: